Dosing underway in early trial of twice-yearly wet AMD treatment
The first patient has been dosed in a phase 1 clinical trial evaluating EYP-1901 for the treatment of wet age-related macular degeneration, according to a press release from EyePoint Pharmaceuticals.
DAVIO is an open-label, dose-escalation trial investigating EYP-1901 (Durasert sustained-release technology with vorolanib) in 13 patients with wet AMD who were responsive to previous anti-VEGF treatments. The insert has the potential to offer a twice-yearly sustained delivery treatment for wet AMD.
“The potential efficacy of vorolanib coupled with the well-characterized safety and predictable drug release kinetics of the Durasert delivery technology offer the potential to provide millions of wet AMD sufferers a convenient and effective treatment option, if approved,” Jay S. Duker, MD, chief strategic scientific officer at EyePoint, said in the release.
The primary endpoint is safety, and key secondary endpoints include best corrected visual acuity and central subfield thickness, the release said.
Read more about